antiIL17

Anti-IL-17 refers to therapies that block the interleukin-17 (IL-17) signaling axis, aimed at reducing inflammatory processes in autoimmune and inflammatory diseases. Most anti-IL-17 medicines are monoclonal antibodies that either neutralize IL-17 cytokines (such as IL-17A or IL-17F) or inhibit the IL-17 receptor (IL-17RA) to prevent downstream signaling.

IL-17 family cytokines, primarily IL-17A and IL-17F, are produced by Th17 cells and other immune cells and drive expression of proinflammatory mediators by epithelial and stromal cells. Inhibition of IL-17 signaling reduces chemokine production and neutrophil recruitment, dampening local inflammation in tissues such as skin and joints.

Representative anti-IL-17 agents include secukinumab and ixekizumab, which bind IL-17A; brodalumab, which targets IL-17RA; and bimekizumab, which blocks both IL-17A and IL-17F. These drugs are administered by subcutaneous injection, with dosing tailored to indication and patient factors.

Clinical use: anti-IL-17 therapies have demonstrated efficacy in plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, and some are approved for hidradenitis suppurativa. Safety concerns include increased risk of mucocutaneous infections, particularly candidiasis, potential exacerbation of inflammatory bowel disease, and injection-site reactions. Brodalumab carries a boxed warning related to suicidality; other agents have distinct safety profiles.

Research continues to define the long-term safety and expand indications for anti-IL-17 therapies, with ongoing trials in dermatologic, rheumatologic, and respiratory diseases. As with all immunomodulatory therapies, patient selection and monitoring are important.